Gloucester’s NDA For Romidepsin In CTCL Is Targeted For Submission By Year End
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will present pivotal trial data on the HDAC inhibitor at the American Society of Hematology in December.
You may also be interested in...
MethylGene Revamps Pipeline As Celgene Backs Off HDAC, Sirtuin Collaboration
Firm has high hopes for lifting the clinical hold on MGDC0103.
Gloucester Pharmaceuticals Inc.
Two subtypes of T-cell mediated lymphomas have been very difficult to treat using the existing cytotoxic chemotherapy treatments. CTCL and peripheral T-cell lymphoma (PTCL) patients receiving chemotherapy may experience severe, dose-limiting toxicities and develop resistance to the therapy. Gloucester Pharmaceuticals Inc. is developing a treatment that potentially is more effective than chemo, the company says, and the National Institutes of Health is backing its development.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.